Wegovy
Semaglutide
Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA for chronic weight management in adults and adolescents with obesity or overweight with at least one weight-related comorbidity. It works by mimicking a natural gut hormone, slowing gastric emptying, reducing appetite, and promoting a feeling of fullness, helping patients eat less and lose weight effectively. Combined with diet and exercise, Wegovy has shown significant weight reduction in clinical trials, often surpassing other non-surgical therapies. It’s delivered via a pre-filled pen and is currently considered a leading medical therapy for sustainable weight loss in eligible patients.
- Manufacturer: Novo Nordisk
- Primary Use: Chronic weight management
- Form: Injectable
Common Side Effects
The most common side effects of Wegovy may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal Pain
This is not a complete list. Always consult with your healthcare provider about potential side effects.
Medical Disclaimer
The information provided for Wegovy is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Read our full disclaimer.